Columbus Macro LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Columbus Macro LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 326 shares of the biopharmaceutical company’s stock, valued at approximately $232,000.

Several other large investors have also modified their holdings of REGN. abrdn plc lifted its position in Regeneron Pharmaceuticals by 0.9% in the fourth quarter. abrdn plc now owns 188,451 shares of the biopharmaceutical company’s stock valued at $133,303,000 after purchasing an additional 1,740 shares during the period. Alliance Wealth Advisors LLC UT acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $248,000. CENTRAL TRUST Co boosted its stake in shares of Regeneron Pharmaceuticals by 70.7% in the fourth quarter. CENTRAL TRUST Co now owns 2,466 shares of the biopharmaceutical company’s stock valued at $1,757,000 after buying an additional 1,021 shares in the last quarter. River Street Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 8.0% during the fourth quarter. River Street Advisors LLC now owns 553 shares of the biopharmaceutical company’s stock worth $394,000 after acquiring an additional 41 shares during the period. Finally, Golden State Equity Partners grew its holdings in Regeneron Pharmaceuticals by 1,479.1% during the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after acquiring an additional 1,272 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Bernstein Bank decreased their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday. Leerink Partners decreased their price objective on shares of Regeneron Pharmaceuticals from $980.00 to $862.00 and set a “market perform” rating on the stock in a report on Tuesday. Oppenheimer dropped their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. BMO Capital Markets decreased their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, Sanford C. Bernstein dropped their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $983.65.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $697.05 on Wednesday. The stock has a market capitalization of $76.60 billion, a price-to-earnings ratio of 17.25, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The stock’s fifty day simple moving average is $719.16 and its 200-day simple moving average is $918.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the company earned $11.86 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.50%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.